About us

Company Overview

Arrien Pharmaceuticals is a "FIELDS" technology driven biopharmaceutical company focused on discovery and development of innovative and effective drug candidates for the treatment of human cancers. The company currently has three drug candidates for oncology and two other programs in development for non-oncology indications.

ARN-6039 completed its Phase 1 clinical trials and was partnered with Boston Pharmaceuticals in 2017.
ARN-3261 is a SIK2 inhibitor in development, competed its IND enabling studies and the anticipated clinical Phase 1a/1b trial to begin in Q1, 2019 in ovarian and other solid tumor patients.

Mission & Values

We believe that our foremost responsibility lies with the millions of patients around the world and our focus is on the discovery and development of new drugs to treat patients where the current therapeutics is inadequate.